About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The VHIR Infectious Diseases research group is made up of medical professionals, with healthcare and clinical or basic translational research activities; of Biomedicine dedicated to basic research; and Nursing, with activities to support clinical research.
The group's lines of research are mainly focused on four areas:
Infections related to immunosuppression. Includes infectious diseases related to immunocompromised patients, solid organ or hematopoietic stem cell transplant recipients and recipients of biological therapies.
Sexually transmitted diseases, including HIV infection and other highly prevalent infections in our country (syphilis, gonorrhea, lymphogranuloma venere or infections caused by the human papillomavirus).
Infections related to health care, with special emphasis on those difficult to treat (cardiovascular infections or infections related to prosthetic materials) or caused by multi-resistant pathogens (MDRO) or affecting vulnerable populations.
Global Health and Tropical Diseases with special emphasis on prevalent diseases in our environment that affect the immigrant or displaced population.
IP: Pere Soler Palacín Collaborators: Antoni Soriano Arandes, Jorgina Vila Soler, Laura Batlle Masó, Natalia Ana Mendoza Palomar, Maria Espiau Guarner, Aurora Fernandez Polo, Núria Worner Tomasa, Laura Lopez Seguer, Miriam Gonzalez Amores, Susana Melendo Perez, Sonia Rodriguez Tello, Andrea Martín Nalda, Claudia Broto Cortes, Marie Antoinette Frick, Jacques Gabriel Rivière Funding agency: Agència Gestió Ajuts Universitaris i de Recerca Funding: 0.01 Reference: 2021 SGR 00441 Duration: 01/01/2022 - 30/06/2025
IP: Israel Molina Romero Collaborators: Juan Espinosa Pereiro, Laia Perez Lasarte Funding agency: Instituto de Salud Carlos III Funding: 65000 Reference: CM22/00246 Duration: 31/03/2023 - 30/03/2025
IP: María José Buzón Gómez Collaborators: Laia Perez Lasarte Funding agency: Instituto de Salud Carlos III Funding: 101250 Reference: CPII22/00005 Duration: 04/01/2023 - 03/01/2026
IP: Meritxell Genesca Ferrer Collaborators: Laia Perez Lasarte Funding agency: VHIR Funding: 225000 Reference: VHIR/SENIORITY/2022/GENESCÀ Duration: 19/10/2022 - 18/10/2027
The study results show that the local presence of IL-1β promotes the development of myeloid cells with an immunosuppressive function.
Funding has been obtained for 43 projects under the calls for Health R&D&I Projects, Health Technology Development, and Independent Clinical Research
More than 50 healthcare professionals and community agents in Benguela receive specialized training to improve the detection and support of women with perinatal disorders.
